Canadian Agency for Drugs and Technologies in Health. (2019). Pharmacoeconomic review report: Risankizumab (Skyrizi) (AbbVie). Canadian Agency for Drugs and Technologies in Health.
Chicago Style (17th ed.) CitationCanadian Agency for Drugs and Technologies in Health. Pharmacoeconomic Review Report: Risankizumab (Skyrizi) (AbbVie). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2019.
MLA (9th ed.) CitationCanadian Agency for Drugs and Technologies in Health. Pharmacoeconomic Review Report: Risankizumab (Skyrizi) (AbbVie). Canadian Agency for Drugs and Technologies in Health, 2019.
Warning: These citations may not always be 100% accurate.